Metformin and Insulin: How They Work Together

Metformin and insulin tackle blood sugar from opposite directions, and that complementary action is exactly why they are so often prescribed together. Metformin primarily dials down the liver’s overproduction of glucose, while insulin helps cells pull glucose out of the bloodstream. When combined in type 2 diabetes, the pairing typically lowers HbA1c more than either drug alone and lets people get by on less insulin than they would otherwise need. But the practical details of how this partnership plays out, who benefits most, and what to watch for are worth understanding beyond the basic pitch.

What Each Drug Actually Does

Insulin’s job is straightforward: it acts as a key that unlocks cells so glucose can enter. When you eat and blood sugar rises, your pancreas releases insulin, which signals muscle, fat, and liver cells to absorb that glucose. At the cellular level, insulin triggers specialized storage vesicles to move glucose transporters to the cell surface, creating doorways for glucose to pass through.¹ In type 2 diabetes, this system breaks down in two ways: the pancreas may not produce enough insulin, and the body’s cells become less responsive to whatever insulin is available.

Metformin works on the other half of the equation. Its primary effect is reducing the amount of glucose your liver dumps into your bloodstream, particularly between meals and overnight. But researchers have come to appreciate that metformin’s action is more complex than just a liver story. There is growing evidence that the gut plays a major role: metformin increases the secretion of GLP-1 (a hormone that stimulates insulin release after eating), changes how glucose is absorbed in the intestines, and reshapes the gut microbiome.² The picture has shifted from “metformin is a liver drug” to “metformin works through multiple pathways we’re still mapping out.”³

Why the Combination Works Better Than Either Alone

The core defect in type 2 diabetes is insulin resistance, which shows up as both excessive glucose production by the liver and reduced glucose uptake by cells.⁴ Injected insulin forces glucose into cells, but it does nothing about the liver’s overproduction problem. Metformin quiets the liver but cannot fully compensate when the pancreas has lost too much of its insulin-producing capacity. Together, they cover both fronts.

There is also a direct interaction between the two drugs that goes beyond each one doing its own thing. Metformin improves how well insulin works at the receptor level, boosting the signaling cascade that insulin uses to get glucose into cells.⁵ In practical terms, metformin makes each unit of injected insulin more effective. This is different from simply adding a second drug; it is amplifying the drug you are already taking.

How Much Better Is Blood Sugar Control?

A meta-analysis pooling results from multiple trials found that adding metformin to insulin therapy in people with type 2 diabetes lowered HbA1c by about 0.8 percentage points more than insulin alone.⁶ That may not sound dramatic, but in diabetes management, a drop of that size meaningfully reduces the risk of complications over time. Individual studies have shown the combination can bring HbA1c below 7% in people whose levels hovered above that threshold on either drug alone.⁷

Older clinical data told a similar story. In a randomized trial comparing the combination against insulin alone, adding metformin reduced mean daily insulin dose requirements by about 17%, dropped HbA1c by nearly a full percentage point, and also improved total cholesterol levels.⁸ The cholesterol benefit is a recurring finding with metformin and is one of several reasons clinicians prefer to keep it in the regimen even after insulin is started.

The Insulin-Sparing Effect

One of the most practical advantages of keeping metformin in the picture is that people need less insulin. Higher insulin doses come with real downsides: more weight gain, greater risk of low blood sugar episodes, and higher medication costs. By improving insulin sensitivity and curbing liver glucose output, metformin allows people to reach the same blood sugar targets on a smaller dose.

This has been documented across diabetes types. In type 1 diabetes, where patients depend entirely on injected insulin, adding metformin reduced daily insulin requirements by roughly 26% in one early study, with the biggest effect seen in the hours after meals.⁹ A more recent randomized trial in adults with type 1 diabetes confirmed a modest but significant reduction in total daily insulin dose over 26 weeks.¹⁰ For someone injecting insulin multiple times a day, even a small per-dose reduction adds up over weeks and months.

Counteracting Insulin-Related Weight Gain

Weight gain is one of the most frustrating side effects of insulin therapy. Insulin is an anabolic hormone: it promotes fat storage, and people on insulin often eat more to guard against low blood sugar episodes. This creates a vicious cycle, because extra weight worsens insulin resistance, which demands more insulin, which drives more weight gain.

Metformin disrupts this cycle. It is weight-neutral or mildly weight-reducing on its own, and when kept alongside insulin therapy, it blunts the weight gain that insulin tends to cause. One study tracked people with type 2 diabetes starting insulin and found that those also on metformin gained significantly less weight: about 3.8 kg over 12 months compared with 7.5 kg in those on insulin without metformin. The difference came down to appetite: the metformin group reduced their calorie intake, while the insulin-only group did not.¹¹ Longer-term data from the HOME trial has confirmed that keeping metformin going after insulin is started prevents much of the insulin-related weight gain.¹²

This is why most clinical guidelines recommend continuing metformin even when a patient progresses to insulin. Dropping metformin to “simplify” the regimen gives up a meaningful weight-management advantage.

Low Blood Sugar Risk When Combining the Two

A common worry is that stacking two glucose-lowering therapies doubles the risk of dangerously low blood sugar. The reality is more nuanced. Metformin on its own almost never causes hypoglycemia, because it does not force the pancreas to secrete more insulin; it just makes the body more responsive to whatever insulin is present. When paired with injected insulin, the hypoglycemia risk comes from the insulin itself, not the metformin.

In a head-to-head comparison, adding insulin to metformin actually produced less hypoglycemia than adding a sulfonylurea (a different class of oral diabetes drug) to metformin.¹³ That said, one large observational study found that the metformin-plus-insulin group did have a somewhat higher rate of hypoglycemia events compared to the metformin-plus-sulfonylurea group when tracked over time.¹⁴ The difference likely reflects the fact that insulin is a more powerful glucose-lowering agent than a sulfonylurea, not that metformin is making the insulin more dangerous. The practical takeaway is that adding metformin to an existing insulin regimen does not meaningfully increase hypoglycemia risk, but starting insulin alongside metformin does require careful dose adjustment because the metformin makes each insulin unit work harder.

Cardiovascular Benefits of the Combination

Beyond blood sugar control, one of the strongest arguments for keeping metformin paired with insulin is what it does for cardiovascular risk. A large retrospective study found that people on insulin plus metformin had a 25% lower risk of major adverse cardiovascular events compared with people on insulin alone.¹⁵ Heart attack, stroke, and cardiovascular death are the leading killers of people with type 2 diabetes, so a treatment combination that improves both sugar control and heart outcomes is doing double duty. Metformin has long been considered to have cardiovascular-protective effects independent of its glucose-lowering action, and these seem to persist even after insulin enters the picture.

The Type 1 Diabetes Question

Metformin is approved for type 2 diabetes, but clinicians have long experimented with adding it for people with type 1 diabetes, hoping that the insulin-sparing and weight benefits would carry over. The results have been mixed in a very specific way.

On the positive side, metformin does reduce insulin dose requirements in type 1 diabetes, as noted earlier. A recent randomized controlled trial also found that this dose reduction occurred through mechanisms separate from improving insulin resistance, since the study found no improvement in liver, muscle, or fat tissue insulin sensitivity after 26 weeks of metformin.¹⁰ The drug may be reducing the amount of glucose entering the bloodstream (through its gut effects) rather than making cells more responsive to insulin.

On the less encouraging side, metformin does not improve HbA1c in type 1 diabetes. The meta-analysis referenced earlier found essentially zero change in blood sugar control when metformin was added to insulin in type 1 patients.⁶ A trial in overweight adolescents with type 1 diabetes similarly found no glycemic benefit, though it did reduce insulin dose and measures of body fat, at the cost of more gastrointestinal side effects.¹⁶ The current evidence does not support routine metformin use in type 1 diabetes for sugar control, though individual patients who struggle with insulin dose-related weight gain may discuss it with their endocrinologist.

Gestational Diabetes and Pregnancy

Gestational diabetes is another context where metformin and insulin sometimes team up. Insulin has long been the standard treatment when blood sugar cannot be controlled by diet and exercise alone during pregnancy, because it does not cross the placenta in meaningful amounts. Metformin does cross the placenta, which has made some clinicians cautious, but it is increasingly used either alone or alongside insulin in gestational diabetes.

The evidence on combining them is promising but not yet definitive. One study found that combining metformin with insulin aspart in gestational diabetes effectively lowered blood sugar and reduced adverse pregnancy outcomes for both mother and newborn.¹⁷ However, a larger propensity-matched study found that obstetric and neonatal complication rates were similar between the combination group and the insulin-only group.¹⁸

The MOMPOD randomized trial looked at adding metformin to insulin early in pregnancy for women with pre-existing type 2 diabetes or early gestational diabetes. The composite adverse neonatal outcome was not reduced by the combination, but babies in the metformin group were less likely to be born large for gestational age, which is a significant concern in diabetic pregnancies because oversized babies face higher delivery risks.¹⁹ The picture here is still evolving. Metformin may help with specific outcomes like fetal size without improving the overall complication rate, and its long-term effects on children exposed in utero remain an active area of research.

Metformin’s Role in PCOS and Insulin Resistance Beyond Diabetes

Polycystic ovary syndrome is one of the most common hormonal conditions in women of reproductive age, and insulin resistance sits at the center of much of its biology. Excess insulin drives the ovaries to produce more androgens, which disrupts menstrual cycles and ovulation. Metformin’s ability to improve insulin sensitivity makes it useful in PCOS even in women who do not have diabetes.

Research has consistently shown that metformin lowers androgen levels, restores more regular menstrual cycles, and can trigger ovulation in women with PCOS.²⁰ Its benefits are particularly pronounced in women who are overweight or have demonstrable insulin resistance, and it may enhance fertility outcomes when combined with other treatments like clomiphene.²¹ While insulin injections are not part of PCOS treatment, the underlying mechanism is the same: metformin reduces how much insulin the body needs to get the job done, and lower circulating insulin means less androgen overproduction.

Vitamin B12 and Long-Term Metformin Use

One side effect that gets overlooked, especially in people taking metformin for years alongside insulin, is vitamin B12 deficiency. Metformin interferes with B12 absorption in the gut, and the risk compounds over time. A real-world database study found that each additional year of metformin use was associated with a 5% increase in the likelihood of B12 deficiency, and people who had been on metformin for four years or more had about 41% higher odds of being deficient compared to shorter-term users.²²

B12 deficiency causes fatigue, numbness, and cognitive fog, symptoms that can easily be mistaken for complications of diabetes itself, particularly diabetic neuropathy. If you are on metformin and insulin and develop new tingling in your hands or feet, it is worth asking your doctor to check your B12 level before assuming the diabetes has worsened. Many guidelines now recommend periodic B12 screening for anyone on long-term metformin.²³

Kidney Function and When to Adjust

The old clinical lore was that metformin should be avoided entirely if there was any hint of kidney trouble, because of a rare but serious side effect called lactic acidosis. That blanket ban has been relaxed considerably as evidence accumulated. Current consensus allows metformin at full dose when kidney filtration rate (eGFR) is 45 or above. Between 30 and 45, metformin can be continued at a reduced dose of up to 1,000 mg per day if a patient is already on it, but should not be newly started. Below 30, metformin is contraindicated.²⁴

This matters for the metformin-insulin combination because kidney function tends to decline as diabetes progresses, and people who eventually need insulin often have more advanced disease. Your doctor will monitor kidney function periodically, and if your eGFR drops into the caution zone, the metformin dose may be cut while your insulin dose is adjusted upward to compensate. Losing metformin’s weight-stabilizing and insulin-sparing effects at this stage is genuinely unfortunate, which is one reason clinicians try to preserve kidney function aggressively throughout the course of diabetes treatment.

Metformin and Cancer Risk

An intriguing line of research that has developed alongside the diabetes work is metformin’s association with lower cancer risk. Multiple observational studies and meta-analyses have linked metformin use to reduced rates of several cancers, particularly pancreatic, colon, and liver cancers.²⁵ People with type 2 diabetes already face elevated cancer risk compared to the general population, partly because high insulin levels promote cell growth. Metformin’s ability to lower circulating insulin is one proposed explanation for its anticancer associations, though the full mechanism remains unclear.

This is still observational evidence rather than a proven treatment effect, and no one should take metformin purely for cancer prevention at this point. But for someone already on metformin and insulin for diabetes, the potential cancer-risk reduction is an additional reason not to drop metformin from the regimen prematurely. Clinical trials testing metformin as an adjunct to cancer treatment are underway in several tumor types, and the next decade should clarify whether these associations hold up under experimental scrutiny.